Tracked shipping to New Zealand with premium packaging for just NZ$15 

Ship to
New Zealand
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium Held in Adjunction with the Second International Conference on
Type
Physical Book
Publisher
Author
Language
English
Pages
112
Format
Paperback
Dimensions
23.4 x 15.6 x 0.7 cm
Weight
0.19 kg.
ISBN13
9781461296188
Categories

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium Held in Adjunction with the Second International Conference on

Kisner, Daniel L. ; Smyth, J. F. (Author) · Springer · Paperback

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium Held in Adjunction with the Second International Conference on - Kisner, Daniel L. ; Smyth, J. F.

Cheaper New Book Imported to New Zealand
Delivery: 21 Aug - 01 Sep Shipping: 12 to 14 business days.
NZ$ 248.70
Faster New Book Imported to New Zealand
Delivery: 11 Aug - 18 Aug Shipping: 4 to 5 business days.
NZ$ 303.66
Import costs and 15% GST included in the price ✅
NZ$ 248.70

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium Held in Adjunction with the Second International Conference on"

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus- cular and subcutaneous routes. Clinical toxicity principally involves the 'influen- za like' syndrome previously seen with native interferons. Other important toxi- cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non- Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea- ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna- tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e., in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews